


LITHIUM - Patients newly prescribed Lithium



Title	LITHIUM - Patients newly prescribed Lithium
Description of policy	<i>To inform healthcare professionals</i>
Scope	<i>Norfolk and Waveney Integrated Care System</i>
Prepared by	Norfolk and Waveney ICB Medicines Optimisation Team
Impact Assessment (Equalities and Environmental)	<p><i>Please indicate impact assessment outcome:</i></p> <p>Positive impact</p> <p><i>Adverse impact - low - action plan completed as per guidance</i></p> <p><i>Adverse impact - medium - action plan completed as per guidance</i></p> <p><i>Adverse impact - high - action plan completed as per guidance</i></p> <p><i>No impact</i></p> <p>No policy will be approved without a completed equality impact assessment</p>
Other relevant approved documents	Lithium shared care agreement
Evidence base / Legislation	<p>Level of Evidence:</p> <p><i>A. based on national research-based evidence and is considered best evidence</i></p> <p>B. mix of national and local consensus</p> <p><i>C. based on local good practice and consensus in the absence of national research based information.</i></p>
Dissemination	Is there any reason why any part of this document should not be available on the public web site? <input type="checkbox"/> Yes / No <input checked="" type="checkbox"/>
Approved by	<i>Norfolk & Waveney Therapeutics Advisory Group (TAG) July 2025</i>
Authorised by	<i>Medicines Optimisation Programme Board on behalf of the ICS (July 2025)</i>
Review date and by whom	Medicines Optimisation Team – July 2027
Date of issue	July 2025

Version Number	Author	Purpose / Change	Date
1.0	MO Team	To support prescribing	July 2025